Citigroup Inc Novo Cure LTD Call Options Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 09, 2023	SELL	$16.15 - $42.35 $6.93 Million - $18.2 Million	-429,000 Reduced 89.56%	50,000 $807,000
Q2 2023 Aug 10, 2023	BUY	$40.29 - $82.51 $463,335 - $948,865	11,500 Added 2.46%	479,000 $19.9 Million
Q1 2023 May 11, 2023	BUY	$56.44 - $118.81 $26.4 Million - $55.5 Million	467,500 New	467,500 $28.1 Million
Q4 2021 Feb 10, 2022	BUY	$75.08 - $121.99 $8.65 Million - $14.1 Million	115,200 New	115,200 $8.65 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.25B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.